Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2025 05:00 ET | Source: Confo Therapeutics

Confo Therapeutics Nominates SSTR5 Agonist Antibody CFTX-2034 as Development Candidate for Post-Bariatric Hypoglycemia

Confo Therapeutics nominates SSTR5 agonist antibody CFTX-2034 as its development candidate for post-bariatric hypoglycemia (PBH).